Cas:60676-51-9 (Z)-Methyl 2-acetylamino-3-phenylacrylate manufacturer & supplier

Chemical Name:(Z)-Methyl 2-acetylamino-3-phenylacrylate

CAS.NO:60676-51-9

Synonyms:2-AcetylaMino-3-phenyl-acrylic acid Methyl ester (Z)-Methyl2-acetylaMino-3-phenylacrylate;2-Propenoicacid,2-(acetylamino)-3-phenyl-,methylester,(2Z);methyl (Z) 2-acetylaminocinnamate;(Z)-methyl-2-acetamido-3-phenylacrylate

Molecular Formula:C₁₂H₁₃NO₃

Molecular Weight:219.23700

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:55.40000

Exact Mass:219.09000

LogP:1.72750

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-AcetylaMino-3-phenyl-acrylic acid Methyl ester (Z)-Methyl2-acetylaMino-3-phenylacrylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(Z)-methyl-2-acetamido-3-phenylacrylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Propenoicacid,2-(acetylamino)-3-phenyl-,methylester,(2Z) Use and application,(Z)-methyl-2-acetamido-3-phenylacrylate technical grade,usp/ep/jp grade.

Related News: However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future. (Z)-Methyl 2-acetylamino-3-phenylacrylate manufacturer But it has been barred from that body as Beijing has increased pressure on Taiwan under President Tsai Ing-wen, who is skeptical about closer ties with China. (Z)-Methyl 2-acetylamino-3-phenylacrylate supplier However, the study did not produce any significant benefits when it came to thinking, reasoning and memory tests performed across the entire patient group — possibly because there were too few people with clinically diagnosed Alzheimer’s participating in the trial. (Z)-Methyl 2-acetylamino-3-phenylacrylate vendor However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future. (Z)-Methyl 2-acetylamino-3-phenylacrylate factory This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?